Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 09/17 11:31:37 am
77.44 CHF   -0.58%
09/17NOVARTIS AG : Deutsche Bank sticks Neutral
MD
09/17NOVARTIS : Releases Results For Efficacy Of Alpelisib Drug
MT
09/17PRESS RELEASE : Novartis announces findings from a -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Sell rating from JP Morgan

07/28/2021 | 07:05am EDT

The analyst from JP Morgan, Richard Vosser, maintains his advice to sell. Previously set at CHF 80, the target price has been raised to CHF 84.


© MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
09/17NOVARTIS AG : Deutsche Bank sticks Neutral
MD
09/17NOVARTIS : Releases Results For Efficacy Of Alpelisib Drug
MT
09/17PRESS RELEASE : Novartis announces findings from a -2-
DJ
09/17PRESS RELEASE : Novartis announces findings from a real-world study of alpelisib..
DJ
09/17Novartis announces findings from a real-world study of alpelisib demonstratin..
DJ
09/17NOVARTIS : Study Shows Potential of Radioligand Therapy in Prostate Cancer
MT
09/17NOVARTIS : Therapy Delays Difficult-To-Bear Symptoms in Late-Stage Prostate Canc..
MT
09/16Novartis Prostate-Cancer Treatment Gets Positive Quality of Life Data
DJ
09/16Novartis reports positive health-related quality of life data for 177Lu-PSMA-..
DJ
09/16PRESS RELEASE : Novartis reports positive health-related quality of life data fo..
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 994 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 373 M - -
P/E ratio 2021 18,3x
Yield 2021 3,94%
Capitalization 186 B 186 B -
EV / Sales 2021 4,00x
EV / Sales 2022 3,73x
Nbr of Employees 109 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 83,04 $
Average target price 103,75 $
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-7.42%186 081
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456